Key factors
sym | NVAX |
exch | US |
MCap | 544.41M |
Beta | 1.602 |
EPS | -5.41 |
Div date | 0000-00-00 |
Yesterday
sym | NVAX |
exch | US |
close | 4.19 |
50 Day MA | 4.676 |
200 Day MA | 6.123 |
52 Week High | 11.36 |
52 Week Low | 3.532 |
Target Price | 15.4 |
Market Cap Mln | 544.41 |
Share statistics
Shares Outstanding | 139.95M |
Shares Float | 123.70M |
Percent Institutions | 57.44 |
PercentInsiders | 4.994 |
SharesShort | 43.90M |
Short Ratio | 5.45 |
Shares Short Prior Month | 48.12M |
Short Percent | 36.57 |
Income
Revenue TTM | 983.70M |
Revenue Per Share TTM | 9.762 |
Quarterly Revenue Growth YOY | -18.5 |
Gross Profit TTM | -156.0M |
EBITDA | -510.9M |
Diluted Eps TTM | -5.41 |
earning
Operating Margin TTM | -0.63 |
EPS Estimate Current Quarter | -0.45 |
EPS Estimate Current Year | -0.73 |
EPS Estimate Next Quarter | -0.05 |
EPS Estimate Next Year | -0.05 |
Earnings Share | -5.41 |
Dividend
Dividend Date | 2019-05-10 |
Last Split Date | 2019-05-10 |
Last Split Factor | 1:20 |
business
Enterprise Value Ebitda | -0.53 |
Enterprise Value Revenue | 0.467 |
Book Value /share | -5.13 |
Price Book MRQ | 49.52 |
Price Sales TTM | 0.608 |
ProfitMargin | -0.55 |
ReturnOnAssetsTTM | -0.17 |
ReturnOnEquityTTM | -8.98 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Biotechnology |
Gic Sector | Health Care |
Gic Sub Industry | Biotechnology |
Industry | Biotechnology |
Sector | Healthcare |
Codes
ISIN | US6700024010 |
CIK | 1000694 |
Code | NVAX |
CUSIP | 670002401 |
Employer Id Number | 22-2816046 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2024-04-19 |
Home Category | Domestic |
info
Fiscal Year End | December |
ForwardPE | 1.781 |
Full Time Employees | 1543.0 |
IPODate | 1995-12-05 |
International Domestic | International Domestic |
MostRecent Quarter | 2023-12-31 |
Contact
Name | Novavax Inc |
Address | 700 Quince Orchard Road, Gaithersburg, MD, United States, 20878 |
Country Name | USA |
Phone | 240 268 2000 |
Web URL | https://www.novavax.com |
Logo URL | /img/logos/US/nvax.png |
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.